ABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICER
January 24 2018 - 1:00AM
YASTEST
GHENT, Belgium,
24 January 2018 - Ablynx [Euronext Brussels
and Nasdaq: ABLX] today announced the appointment of Robert
Friesen, PhD, as Chief Scientific Officer (CSO), effective 1 March
2018. Dr Friesen will lead the Company's scientific, research and
technology activities and become a member of the Executive
Committee. He succeeds Dr Antonin de Fougerolles, Ablynx's previous
CSO, who left the Company last year to become Chief Executive
Officer (CEO) at Evox Therapeutics.
Dr Friesen has more than 20 years
of experience in the biopharmaceutical industry, leading multiple
Research and Development (R&D) organisations. Dr Friesen joins
Ablynx from ProQR Therapeutics, a clinical stage biotechnology
company, where he is currently Senior Vice President, heading the
Science and Early Development division. Prior to joining ProQR
Therapeutics, Dr Friesen worked at Janssen BioTherapeutics, a
Johnson & Johnson Company as Global Head of Biologics Research,
where he established an efficient R&D organisation of more than
200 scientists and professionals located in Europe and US; and at
the Crucell Vaccine Institute, a Johnson & Johnson Company, as
Vice President Preclinical and Clinical Research where he led the
team responsible for discovery, production and preclinical
development of monoclonal antibodies. Before Crucell Vaccine
Institute, he was Head of Preclinical & Early Clinical
Development at MorphoSys.
Dr Friesen holds a PhD in
biochemistry from the University of Texas and performed
postdoctoral research at the University of Groningen.
Welcoming Dr
Friesen to the team, Dr Edwin Moses, CEO of Ablynx,
said:
"Robert brings an extensive track record of successfully initiating
and executing new drug discovery programmes as well as building
strong research organisations. We are pleased to have him join our
team and lead our company's research activities at such an
important and exciting time for Ablynx. We will be able to leverage
his critical expertise and proven leadership capabilities as we
expand our proprietary Nanobody product pipeline and execute on our
multiple strategic collaborations with major pharmaceutical
companies. We look forward to welcoming Robert as we continue to
advance our leading Nanobody platform to deliver meaningful
products to patients around the world, and create substantial value
for Ablynx's shareholders."
Commenting on his
appointment, Dr Friesen added:
"I have long admired Ablynx and am excited to join the Company at
such an important time. With Ablynx's upside potential, I look
forward to meaningfully contributing to Ablynx's momentum and
advancing our leading Nanobody platform to help drive forward the
Company's strategy of becoming a fully integrated biopharmaceutical
company. With Ablynx's strong pipeline, platform and technology, I
am confident that our talented team will continue to deliver novel
products to patients that address unmet medical needs where there
are currently limited or no therapeutic options."
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Apr 2023 to Apr 2024